Drugmaker Wockhardt's pending regulatory issues with US Food and Drug Adminstration is getting murkier as the latest observations made by the US drug regulator suggests the Indian drugmaker has manipulated data related to tests and trials of drugs. Mint's C H Unnikrishnan has more.
